ATN1 Modulation Oligonucleotides for Neurodegenerative Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for efficiently silencing ATN1 mRNA expression, which is associated with dentatorubral-pallidoluysian atrophy (DRPLA), a neurodegenerative disorder caused by expanded CAG repeats in the ATN1 gene, leading to progressive neurological symptoms.
Innovation Solution
Development of RNA molecules, specifically double-stranded RNA (dsRNA) with sequences complementary to ATN1 nucleic acid sequences, designed to inhibit ATN1 gene expression by targeting and degrading ATN1 mRNA, using pharmaceutical compositions and delivery systems that administer dsRNA to relevant brain regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current silencing methods are used, then ATN1 mRNA expression can be reduced, but the silencing efficiency is insufficient
Solution Approach 1:
The patent modifies the chemical structure of RNA molecules by incorporating 2'-O-methyl modifications and phosphorothioate backbone linkages. These parameter changes in the molecular structure enhance both the stability and silencing efficiency of the RNA interference agents against ATN1 mRNA, directly addressing the insufficient efficiency of current methods
Solution Approach 2:
The invention uses composite RNA structures combining modified nucleotides (2'-O-methyl ribonucleotides) with standard phosphorothioate backbones. This composite material approach creates RNA molecules that are both highly efficient at silencing ATN1 mRNA and resistant to degradation, resolving the contradiction between reliability and productivity of gene silencing
2Reliability
If dsRNA is administered to brain regions, then ATN1 gene expression is reduced by 50% or more, but delivery complexity increases
Solution Approach 1:
The patent employs phosphorothioate-modified RNA molecules as intermediaries that facilitate delivery to brain regions. These modified RNA agents serve as mediators between the administration system and target ATN1 mRNA, achieving 50% or greater gene expression reduction while the molecular modifications themselves enhance stability and reduce the need for complex delivery mechanisms
Solution Approach 2:
By changing the chemical parameters of the RNA molecule (2'-O-methyl modifications and phosphorothioate backbone), the patent enhances the molecule's stability and target specificity. This allows for effective brain region delivery with reduced complexity, as the modified RNA molecules are more resistant to degradation and have improved pharmacokinetic properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA effectively reduces ATN1 gene expression by 50% or more in specific brain areas, providing a therapeutic approach to manage DRPLA and other trinucleotide repeat disorders.
Implementation Method 1
double-stranded RNA (dsRNA) with sequences complementary to ATN1 nucleic acid sequences, designed to inhibit ATN1 gene expression by targeting and degrading ATN1 mRNA
Implementation Method 2
degrading the mRNA transcript of the ATN1 gene, thereby inhibiting expression of the ATN1 gene in the cell
Data Source
AI summary
This disclosure relates to novel ATN1 targeting sequences. Novel ATN1 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.